Genomic sequencing and lung cancer: the study which shows a survival gain thanks to biomarkers

Genomic sequencing and lung cancer: the study which shows a survival gain thanks to biomarkers
US data links broader genomic testing before treatment to longer survival in advanced lung cancer. In France, the useful question mainly concerns the biomarkers sought and the deadlines.

When treatment is to begin, one question may seem very technical: has the tumor been sufficiently analyzed? In the non-small cell lung cancer (NSCLC), these tests can guide targeted therapy when a relevant molecular abnormality is found.

An American study published in the JNCCN—Journal of the National Comprehensive Cancer Networkpresented by the National Comprehensive Cancer Network, associates broad genomic sequencing before treatment with longer survival. For a patient, the right question is not to ask for a specific test, but to ask what biomarkers are being looked for, if the results are available or expected,
without delaying urgent treatment.

What does this American study really show?

The press release reports an analysis of real-life data from electronic health records, the Flatiron Health Research Database. It concerns more than 35,000 patients with advanced NSCLC, treated in community and academic oncology centers in the United States between 2016 and 2022.

The researchers compared patients who had, before the first line of treatment, broad genomic sequencing – a panel looking for numerous alterations in a single analysis – with patients tested in a more restricted way, on one or two biomarkers. The press release reports a difference of approximately two months in overall survival in favor of the extensively tested group, as well as a modest improvement in progression-free survival.

Another signal: patients in the broad sequencing group received targeted therapy more often, 19% compared to 16% in the narrower testing group. This is in line with a simple idea: the earlier the tumor is characterized, the greater the probability of identifying a suitable therapeutic option when it exists.

Why does the word “association” matter so much?

This study does not prove, on its own, that the broad test directly causes a survival gain. This is a retrospective observational analysis on electronic records: even with adjustments, there may remain differences between patients, tumors, access to care or available treatments.

This caution is all the more important since an older study published in the JAMAalso based on Flatiron data but over an earlier period, had not found a clear independent association between broad sequencing and better survival. The context has changed since then, with more biomarker-guided treatments; this makes the new result interesting, but not definitive.

The press release cites in particular EGFR, ALK, ROS1, KRAS G12C, MET, RET and BRAF among the biomarkers useful for decision-making. These are important benchmarks, but they do not alone summarize the French organization or all the tests to consider in a care pathway.

In France, what to ask without wasting time?

The National Cancer Institute’s guidelines updated for 2025-2026 specify that at the metastatic stage, before the first line, certain markers are essential, in particular PD-L1, EGFR mutations and fusions such as ALK, ROS1 or RET. When the local organization allows it, a direct search by NGS is recommended, with a minimal panel which may include in particular KRAS G12C, BRAF, ERBB2/HER2, MET exon 14, NTRK and MET amplification.

In other words, the “broad test” does not necessarily mean a panel of hundreds of genes for everyone. In practice, the challenge is that molecular tests for lung cancer cover the necessary biomarkers within timeframes compatible with the therapeutic decision. The INCa indicates an ideal period of 7 calendar days from the anatomopathological diagnosis, a maximum of 14 days for essential biomarkers, and a period not exceeding 3 weeks for multiplexed tests.

Tissue biopsy remains the reference standard. The High Authority for Health, however, recognizes targeted sequencing of circulating tumor DNA as a non-invasive alternative in specific situations: therapeutic emergency, non-contributory tissue analysis or impossibility of carrying it out.

For patients and relatives, the most useful formulation in consultation is in one sentence: “What biomarkers were looked for, by what method, and are the results available before choosing the treatment?“. This question can help make the journey safer without transforming the patient into a genomics expert.